

July 15, 2024

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

To,  
The Manager – Listing  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLENMARK

To,  
Glenmark Life Sciences Limited  
Plot No 170-172  
Chandramouli Industrial Estate  
Mohol Bazarpeth, Solapur 413 213

Dear Sir/Madam,

**Sub: Disclosure under Regulation 31(2) read with Regulation 28(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011**

Pursuant to Regulation 31(2) read with Regulation 28(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011, as prescribed pursuant to the Master Circular for Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011, bearing reference no. SEBI/HO/CDF/PoD-1/P/CIR/2023/31, dated February 16, 2023, please find attached disclosure in relation to the shares of Glenmark Life Sciences Limited in **Annexure A**.

This is for your information and records.

Yours faithfully,  
For **Glenmark Pharmaceuticals Limited**



**Harish Kuber**  
Company Secretary & Compliance Officer  
Encl: As above



Annexure A

Disclosure by the Promoter to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of Target Company (TC)		Names of the stock exchanges where the shares of the target company are listed		Date of reporting	Name of the promoter or PAC on whose shares encumbrance has been created/released/invoked								
Glenmark Life Sciences Limited ("GLS")		BSE Limited and National Stock Exchange of India Limited		July 15, 2024	Glenmark Pharmaceuticals Limited ("GPL")								
Details of the creation of encumbrance:													
Name of the promoter (s) or PACs with him	Promoter holding in the target company (1)	Promoter holding already encumbered (2)	Details of events pertaining to encumbrance (3)				Post event holding of encumbered shares {creation [(2)+(3)] / release [(2)-(3)] / invocation [(1)-(3)]}						
Number	% of total share capital	Number	% of total share capital	Type of event (creation / release / invocation)	Date of creation/ release/ invocation of encumbrance	Type of encumbrance (pledge/ lien/ non disposal undertakin g/ others)	Reasons for encumbrance	Number	% of total share capital	Name of the entity in whose favor shares encumbered	Number	% of total share capital	
Glenmark Pharmaceuticals Limited [(including its nominee shareholders)]*	96,09,571	7.84%	96,09,571	7.84%	Release	July 4, 2024	Non-Disposal Undertaking	The non-disposal undertaking was waived pursuant to execution of the letter	96,09,571	7.84%	Nirma Limited	Nil	Nil



